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INTRODUCTION
Research has shown that medical school students and
graduating pharmacy students desire more education on
the appropriate use of antimicrobials, a key component of
antimicrobial stewardship (AMS), which aims to resolve the
patient’s infection, minimize antimicrobial resistance, and
reduce toxicities associated with antimicrobial use (1, 2).
Per the Infectious Diseases Society of America (IDSA) and
the Society for Healthcare Epidemiology of America
(SHEA), the primary goal of AMS is to optimize clinical
outcomes for the patient and minimize consequences of
antimicrobial use, such as toxicities, selection for opportunistic pathogens such as Clostridioides difﬁcile, and antimicrobial resistance (3). An interprofessional curriculum
on AMS geared toward preclinical medical and pharmacy
students was shown to positively inﬂuence not only AMS
but also professional collaboration (4). Signiﬁcantly more
students who participated in this curriculum could
describe the function of the medical and pharmacy professions in appropriate antimicrobial use, communicate in
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an interprofessional manner, and ﬁnd ways to collaborate
with each other (4). Even though 65% of medical schools
in the United States teach AMS during preclinical years,
most of these schools have focused largely on didactic
lectures, with only a few offering opportunities for interprofessional education in stewardship (5). There has not been an
overt request for AMS inclusion as part of preclinical education. For instance, the 2015 IDSA Stewardship Commitments
for the White House Forum on Antibiotic Stewardship position
statement bypassed AMS education of health professions students as one of its commitments (6). Guidelines by IDSA and
SHEA recommend that academic medical centers and teaching hospitals integrate AMS education into their preclinical
and clinical curricula (7). This article highlights the challenges
of stewardship in the midst of a ﬂuid and uncertain pandemic.
It reiterates the importance of education at all levels so that
future health care providers have good foundational knowledge of AMS and integrate the principles in their future clinical practice.
The use of broad-spectrum antibiotics as a component of
COVID-19 treatment may be justiﬁed when you consider the
overlap of some respiratory symptoms of bacterial community-acquired pneumonia with that of COVID-19, such as
cough, fever, and shortness of breath. Compounding this issue
is the fact that the risk of COVID-19 severity and hospitalizations increase with age and/or presence of underlying medical
conditions, both of which are also risk factors for other infections (8).
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As the world deals with a pandemic, there remains another global challenge that cannot be ignored. Use
of broad-spectrum antibiotics may be justiﬁed, as we are trying to treat a novel disease condition, which,
in turn, could lead to an increase in antimicrobial resistance. We can decrease morbidity, mortality, and
health care costs by controlling antimicrobial resistance, but it requires antimicrobial stewardship. Major
components of effective and timely antimicrobial stewardship are diagnostic stewardship, infection prevention and control, and integration of COVID-19-speciﬁc ﬂags into electronic health records, all of which
may be integrated into current strategies of COVID-19 mitigation and management. Going through the
inﬂuenza season of 2020, implementation of antimicrobial stewardship education efforts in the United
States can help us contend with inﬂuenza in addition to COVID-19 and any bacterial coinfections or secondary infections. Additional solutions include the development of vaccines, alternative therapies, such as
antibodies, and advanced diagnostics using advances in genomics and computer science.
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METHODS
To establish the signiﬁcance of what we are proposing,
we have reviewed some of the noteworthy papers in antimicrobial resistance and AMS, such as the CDC report on
antimicrobial resistance, economist Jim O’Neill’s ﬁnal report
to the United Kingdom government on tackling drug-resistant infections globally, as well as the SHEA guidelines for
health care epidemiologists in U.S. acute-care hospitals. In
addition, we reviewed a few 2020 publications on AMS in
the midst of COVID-19 along with select publications on
the importance of diagnostic stewardship. Since we would
like all medical schools to include teachings on AMS principles, we also reviewed some of the important publications
discussing this topic. In addition, we have summarized some
2

of the challenges in upholding principles of stewardship in
the midst of seasonal inﬂuenza, past inﬂuenza pandemics,
and the current pandemic.

RESULTS
It is time to seriously think of AMS and revisit institutional policies as we head into inﬂuenza season. A 2016
research study involving 322 patients hospitalized with inﬂuenza revealed that most patients received antibiotics upon
admission, with more than one-third being inappropriately
continued on antibiotics despite a lack of evidence of bacterial infection (13). Traditionally, there have not been any formal recommendations for inclusion of AMS programs in disaster planning or emergency preparedness efforts (14).
COVID-19 is underscoring the need to have AMS programs
integrated with hospital infection prevention programs (15).
A review of scientiﬁc literature describing clinical outcomes
of the 2009 pandemic inﬂuenza virus infection revealed secondary bacterial infection in almost 25% of severe or fatal
cases (16). There is a need to prospectively monitor coinfections in patients with COVID-19 to understand whether
coinfection affects disease progression and, at the same
time, enables AMS (17).
A major component of effective and timely AMS is diagnostic stewardship, which includes the process of ordering
and interpreting diagnostic tests before initiating or continuing treatment (18). Interpretation of sensitive molecular
tests that detect multiple targets simultaneously or use of
next-generation sequencing tests that detect microbial
genomes must also take into account the pretest likelihoods
of infection with each target in the test (19). Use of rapid
diagnostics enables early diagnosis, leading to the use of targeted antimicrobials and bypassing the misuse of empirical
antimicrobials. However, diagnosis has to be considered in
the context of colonization versus an actual infection, with
the latter being distinguished by the presence of diseasecausing microorganisms on or in the body of a patient and
the former being characterized by microbial presence without disease (20). Hospitals have to continue efforts to distinguish between the two. For instance, laboratory policies
may enforce strict conditions of specimen collection and/or
handling before specimens are processed, thereby minimizing contamination with colonized microorganisms (19).
Tests may also be performed in a stepwise fashion, with subsequent tests dependent on results from the previous tests
(19). Some hospitals provide ongoing education to their
clinicians about appropriate indications and sampling for
tests. A multidisciplinary expert panel of IDSA and SHEA recommended not relying solely on didactic educational materials
for stewardship and encouraged academic medical centers as
well as teaching hospitals to integrate AMS education into
their preclinical and clinical curricula (7). To achieve sustained
stewardship, education has to be combined with other AMS
efforts, like prospective audit and feedback (PAF), an external,
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Prescribing antibiotics for a viral infection, even one
without a U.S. Food and Drug Administration-approved
standard of care, has to be considered in the context of
antimicrobial resistance. The current pandemic, with its
urgent need of treating a disease, the progression of which
is being scientiﬁcally investigated in real time, has the potential to increase antimicrobial resistance (9). The inappropriate prescription of antibiotics despite the lack of evidence
of bacterial coinfections in patients with COVID-19 will
inevitably worsen antimicrobial resistance (10). More than
2.8 million antibiotic-resistant infections occur in the United
States each year, and more than 35,000 people die as a
result (11). At last count, which was in 2017, nearly 223,900
people in the United States required hospital care for the
opportunistic pathogen Clostridioides difﬁcile, and at least
12,800 people died from this preventable infection (11). C.
difﬁcile infections are caused by the same factors that drive
antibiotic resistance: antibiotic use and transmission of infectious agents. The increase in resistant infections in the
community not only puts more people in the community at
risk of these infections but also makes transmission harder
to identify and contain, thereby threatening the progress
made to protect patients in health care (9). Antibiotic resistance disproportionally impacts the young, elderly, and
sick, who are the most vulnerable individuals who receive
medical care often. However, technically anyone would be
at risk of infection with resistant pathogens. Infections with
drug-resistant pathogens are harder and more expensive to
treat and result in increased morbidity and mortality as well
as extended length of hospital stay (12). These resistant
pathogens spread from patient to patient within hospitals
and across health care facilities through patient transfer, and
they eventually spill over into communities, becoming much
harder to control (11). It may be a few years before we realize the impact of the pandemic on the incidence of antibiotic-resistant infections. What is vital is our continued
effort to measure and improve how antimicrobials are prescribed by clinicians and used by patients, which, in essence,
is AMS.
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urgent consideration. The report estimated that by 2050,
300 million premature deaths may occur as a result of antimicrobial resistance, with an anticipated loss of between 60 and
100 trillion U.S. dollars in economic output if antimicrobial
resistance is not tackled (26). The current pandemic, with its
unique challenges of diagnosis, uncertainty of the extent of
morbidity and mortality, doubts about immunity in recovery,
and lack of focused AMS program efforts, will only worsen
this issue. Now, more than ever, we have to incorporate the
lessons proposed in economist Jim O’Neill’s 2016 report,
including, but not limited to, the development of vaccines, alternative therapies such as antibodies, advanced diagnostics
using advances in genomics and computer science, and continued infection prevention and control efforts (26).

DISCUSSION
As our frontline providers faced burnout in a health
care system overwhelmed by the novelty of the disease,
lack of adequate protective equipment, lack of adequate
testing (at least initially), delays in receiving laboratory-conﬁrmed results, and uncertainty on how best to manage the
illness, it is understandable if there was an initial incorporation of broad-spectrum antibacterial use. As we go through
fall 2020, it is worth remembering that bacterial superinfections in past inﬂuenza seasons have presented either as initial coinfections with inﬂuenza virus or as secondary bacterial infections in patients hospitalized with inﬂuenza (27).
One of the complications in COVID-19 is pulmonary distress that results in respiratory failure, acute respiratory
distress syndrome, or even ventilator-associated pneumonia, all of which can be fatal (28). Previous inﬂuenza pandemics have underscored the importance of treating for secondary
bacterial pneumonia, which can be fatal if untreated (16).
To meet the rigors of diagnostic stewardship, EHRs can
be designed to provide a more meaningful process for
ordering diagnostic tests (15). When implemented thoughtfully, EHRs can facilitate a culture of AMS, disease surveillance (identifying potential disease spread based on monitoring symptoms among a population at risk), and seamless
transfers in care that successfully transition the management of patients between facilities (29). When health care
facilities incorporate AMS program ﬂags, regardless of facility compliance with the AMS program ﬂags, periodic
reviews of the ﬂags by the infectious diseases team will provide the health care community an indication of the nature
of the COVID-19 AMS program (24). What is most timely
and intelligent about this approach is its ﬂexibility in modifying ﬂag rules based on changes in community prevalence of
COVID-19 and/or testing recommendations. It would be
prudent to adopt this approach to AMS programs in general, adapting rules based on changes in antibiograms and/or
availability of diagnostic tests. However, incorporating alert
ﬂags into the existing EHR may require appropriate training
of personnel serving on the infectious diseases team. In the
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expert review of antibiotic therapy with suggestions to optimize use (7).
It is important to include the role of animals in our
AMS education efforts. Antimicrobial resistance is compounded by the frequent and heavy use of antimicrobials in
our food animals, making animals a crucial player in the
spread and evolution of resistant pathogens (21). Even the
microbiota of wild animals is being acknowledged as a reservoir of resistance genes (21). Research has also shown that
reduction of antibiotic use in food animals is accompanied
by a reduction in antibiotic-resistant bacteria in animals as
well as in humans directly exposed to these animals (22).
Not surprisingly, timely, accurate diagnosis greatly increases
the likelihood of improving clinical care and patient health.
Proper diagnostic stewardship is a process that involves selecting the correct (or as nearly correct as possible) diagnostic test
for the appropriate patient with a certain clinical scenario, followed by timely collection of the relevant clinical specimen, its
transport and processing, and timely reporting of test results
(23). However, ongoing evaluation and careful monitoring of
diagnostic stewardship is necessary, as overuse of some rapid
tests can increase health care costs without improving patient
care, while underuse may delay diagnosis and patient recovery
(18). Serving as an example of utilizing existing infrastructure to
meet the demands of AMS programs while managing COVID19, the Mayo Clinic modiﬁed its prospective audit system by
integrating two COVID-19-speciﬁc AMS program ﬂags into
their electronic health records (EHRs) (24). The ﬁrst AMS program ﬂag rule identiﬁed in-patients with a negative SARS-CoV-2
reverse transcription-PCR (RT-PCR) test within the last week
and who were already on COVID-19 medications, as indicated
by active therapy, which was hydroxychloroquine in this case.
The second AMS program ﬂag rule identiﬁed laboratory-conﬁrmed COVID-19 patients and triggered review by an
Infectious Diseases team. This second AMS program ﬂag also
identiﬁed pending patients with an active therapy order, who, if
RT-PCR negative, reverted to the ﬁrst ﬂag rule and, if RT-PCR
positive, prompted review by the Infectious Diseases team. The
ﬂag rules met the goals of providing patients with the beneﬁt of
timely and appropriate care within the conﬁnes of critical medication resources. It is recommended that the contribution of
AMS program ﬂags be considered in relation to the overall EHR
ﬂag burden of a facility to avoid “alert fatigue,” especially in
COVID-19 hot spots with high patient volume (24).
In addition to diagnostic stewardship, another necessary
AMS program component is infection prevention and control. By preventing the occurrence as well as the spread of
infections, evidence-based infection prevention and control
interventions reduce the demand for antimicrobials, thereby
providing an effective antidote to inappropriate and unnecessary antibiotic prescriptions (25). As we confront the hurdles
surrounding implementation of universal masking and other
measures aimed at preventing SARS-CoV-2 infections, the
2016 report on the global impact of antimicrobial resistance,
commissioned by the United Kingdom, shines the spotlight
even brighter on this current crisis that needs ongoing,

upcoming inﬂuenza season, diagnostic stewardship will be
tasked with the urgent need to facilitate timely diagnosis of
inﬂuenza, COVID-19, and any bacterial pathogens either
coinfecting or causing secondary infections. If AMS is not
addressed across all health sectors, it could have devastating
consequences globally for years to come.
Effective AMS programs can dramatically improve patient
care and save more lives. We have to continue to raise awareness and educate our future health care providers. Improving
antibiotic prescribing and use is a national and international
priority (26, 30). It would be prudent for health profession
schools and colleges to educate students about AMS before
they graduate or before they start their clinical rotations.
Knowing about AMS when they learn about early and appropriate diagnoses of infections will help inspire students to
understand the relevance of learning about the different antimicrobials, especially as it would mean use of the appropriate
antimicrobial instead of indiscriminate use of a broad-spectrum
antibiotic. Knowing about AMS when they learn about drugs
will help the students comprehend the relevance of side effects
and/or black box warnings of certain antimicrobials. How AMS
education efforts are undertaken could depend on either guidance from the IDSA or be individualized according to speciﬁc
medical school curriculum.
The current pandemic is underscoring the need to
invest a little time in educating beginner health care providers in AMS so they are aware of the challenges, threats,
and solutions. The current crisis brings renewed attention
to the need to build a heightened awareness of AMS, and
we think it is ideal that it start when students enter the
health professions.
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